There were 1,783 press releases posted in the last 24 hours and 393,357 in the last 365 days.

Short Bowel Syndrome Market is Projected to Grow at a CAGR of 20.52% from 2024-2034 | IMARC Group

BROOKLYN, NY, USA, April 17, 2024 / --  Market Overview:

The short bowel syndrome market is expected to exhibit a CAGR of 20.52% during 2024-2034.The report offers a comprehensive analysis of the short bowel syndrome market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the proportion of various therapies, and the market’s performance in the seven major regions. Additionally, the report evaluates the performance of leading companies and their pharmaceutical products. Current and projected patient numbers across these key markets are also detailed in the report. This study is essential for manufacturers, investors, business planners, researchers, consultants, and anyone interested or involved in the short bowel syndrome market.

Request for a Sample of this Report:

Short Bowel Syndrome Market Trends:

Short bowel syndrome (SBS) is a complex condition that occurs due to the physical absence or malfunctioning of a portion of the small intestine, resulting mainly from surgical resection or congenital disorders. The short bowel syndrome market is witnessing significant growth due to the rising prevalence of the ailment, necessitating specialized medical care and nutritional support. Additionally, advancements in medical technologies, particularly in the fields of surgery and parenteral nutrition, are playing a pivotal role in this market's expansion. These advancements not only improve the quality of life for patients but also extend their life expectancy, thus creating a continual demand for effective SBS treatments.

Moreover, the rising investment in R&D by pharmaceutical companies is another critical driver. This investment is leading to the innovation of new drugs and treatment modalities, further fueling the market's growth. Concurrently, increasing awareness about the disorder and its treatment options, facilitated by patient education programs and advocacy efforts, is enhancing early diagnosis and treatment, thereby contributing to the market growth. Furthermore, the introduction of novel therapeutic agents, which are more effective and have fewer side effects, is anticipated to boost the market substantially. Besides this, the escalating integration of personalized medicine in the treatment of SBS to tailor the certain needs of individual patients based on their lifestyle, genetic makeup, and environment is bolstering the short bowel syndrome market forward.

Countries Covered:

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country:

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the short bowel syndrome market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the short bowel syndrome market
• Reimbursement scenario in the market
• In-market and pipeline drugs

This report also provides a detailed analysis of the current short bowel syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs:

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance

Competitive Landscape With Key Players:

The competitive landscape of the short bowel syndrome market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of the Key Players:

Eli Lilly and Company
Bristol Myers Squibb
Ono Pharmaceuticals
Novartis Pharmaceuticals

Ask Analyst for Customization and Explore Full Report With TOC & List of Figures:

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

Other Reports:

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US:


134 N 4th St. Brooklyn, NY 11249, USA


Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163

Elena Anderson
IMARC Services Private Limited
+ +1 631-791-1145
email us here